Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification.

Schaumann N, Raap M, Hinze L, Rieger L, Schürch CM, Antonopoulos W, Avril S, Krech T, Dämmrich M, Kayser G, Puls F, Länger F, Tinguely M, Kreipe H, Christgen M.

Pathol Res Pract. 2019 Aug 20:152611. doi: 10.1016/j.prp.2019.152611. [Epub ahead of print]

PMID:
31551174
2.

CARving up colorectal cancer organoids in vitro.

Schürch CM.

Genes Immun. 2019 May 20. doi: 10.1038/s41435-019-0079-7. [Epub ahead of print] No abstract available.

PMID:
31105265
3.

A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma.

Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schürch CM, Hamilton M, Robertson N, Lin W, Noel P, Wartenberg M, Zlobec I, Eichmann M, Galván JA, Karamitopoulou E, Gilderman T, Esparza LA, Shima Y, Spahn P, French R, Lewis NE, Fisch KM, Sasik R, Rosenthal SB, Kritzik M, Von Hoff D, Han H, Ideker T, Deshpande AJ, Lowy AM, Adams PD, Reya T.

Cell. 2019 Apr 18;177(3):572-586.e22. doi: 10.1016/j.cell.2019.03.010. Epub 2019 Apr 4.

PMID:
30955884
4.

Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.

Schürch CM, Roelli MA, Forster S, Wasmer MH, Brühl F, Maire RS, Di Pancrazio S, Ruepp MD, Giger R, Perren A, Schmitt AM, Krebs P, Charles RP, Dettmer MS.

Thyroid. 2019 Jul;29(7):979-992. doi: 10.1089/thy.2018.0555. Epub 2019 May 10.

5.

Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Schürch CM.

Front Oncol. 2018 May 18;8:152. doi: 10.3389/fonc.2018.00152. eCollection 2018. Review.

6.

The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma.

Schürch CM, Forster S, Brühl F, Yang SH, Felley-Bosco E, Hewer E.

Oncoimmunology. 2017 Sep 21;7(1):e1373235. doi: 10.1080/2162402X.2017.1373235. eCollection 2017.

7.

Tumor Heterogeneity in Lymphomas: A Different Breed.

Schürch CM, Federmann B, Quintanilla-Martinez L, Fend F.

Pathobiology. 2018;85(1-2):130-145. doi: 10.1159/000475530. Epub 2017 Jul 19. Review.

8.

Innate immunity restricts Citrobacter rodentium A/E pathogenesis initiation to an early window of opportunity.

Buschor S, Cuenca M, Uster SS, Schären OP, Balmer ML, Terrazos MA, Schürch CM, Hapfelmeier S.

PLoS Pathog. 2017 Jun 29;13(6):e1006476. doi: 10.1371/journal.ppat.1006476. eCollection 2017 Jun.

9.

The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells.

Murone M, Radpour R, Attinger A, Chessex AV, Huguenin AL, Schürch CM, Banz Y, Sengupta S, Aguet M, Rigotti S, Bachhav Y, Massière F, Ramachandra M, McAllister A, Riether C.

Mol Cancer Ther. 2017 Aug;16(8):1497-1510. doi: 10.1158/1535-7163.MCT-16-0889. Epub 2017 May 3.

10.

Functional Intestinal Bile Acid 7α-Dehydroxylation by Clostridium scindens Associated with Protection from Clostridium difficile Infection in a Gnotobiotic Mouse Model.

Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, Schürch CM, McCoy KD, Kuehne SA, Minton NP, Stecher B, Bernier-Latmani R, Hapfelmeier S.

Front Cell Infect Microbiol. 2016 Dec 20;6:191. doi: 10.3389/fcimb.2016.00191. eCollection 2016.

11.

CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.

Riether C, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, Zlobec I, Pabst T, Radpour R, Ochsenbein AF.

J Exp Med. 2017 Feb;214(2):359-380. doi: 10.1084/jem.20152008. Epub 2016 Dec 28.

12.

Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling.

Riether C, Schürch CM, Flury C, Hinterbrandner M, Drück L, Huguenin AL, Baerlocher GM, Radpour R, Ochsenbein AF.

Sci Transl Med. 2015 Jul 29;7(298):298ra119. doi: 10.1126/scitranslmed.aab1740.

PMID:
26223302
13.

IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.

Mager LF, Riether C, Schürch CM, Banz Y, Wasmer MH, Stuber R, Theocharides AP, Li X, Xia Y, Saito H, Nakae S, Baerlocher GM, Manz MG, McCoy KD, Macpherson AJ, Ochsenbein AF, Beutler B, Krebs P.

J Clin Invest. 2015 Jul 1;125(7):2579-91. doi: 10.1172/JCI77347. Epub 2015 May 26.

14.

Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells.

Riether C, Gschwend T, Huguenin AL, Schürch CM, Ochsenbein AF.

Leukemia. 2015 Aug;29(8):1781-5. doi: 10.1038/leu.2015.26. Epub 2015 Feb 4. No abstract available.

15.

Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling.

Balmer ML, Schürch CM, Saito Y, Geuking MB, Li H, Cuenca M, Kovtonyuk LV, McCoy KD, Hapfelmeier S, Ochsenbein AF, Manz MG, Slack E, Macpherson AJ.

J Immunol. 2014 Nov 15;193(10):5273-83. doi: 10.4049/jimmunol.1400762. Epub 2014 Oct 10.

16.

Regulation of hematopoietic and leukemic stem cells by the immune system.

Riether C, Schürch CM, Ochsenbein AF.

Cell Death Differ. 2015 Feb;22(2):187-98. doi: 10.1038/cdd.2014.89. Epub 2014 Jul 4. Review.

17.

Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells.

Schürch CM, Riether C, Ochsenbein AF.

Cell Stem Cell. 2014 Apr 3;14(4):460-72. doi: 10.1016/j.stem.2014.01.002. Epub 2014 Feb 20.

18.

Dendritic cell-based immunotherapy for myeloid leukemias.

Schürch CM, Riether C, Ochsenbein AF.

Front Immunol. 2013 Dec 31;4:496. doi: 10.3389/fimmu.2013.00496. Review.

19.

Interferons in hematopoiesis and leukemia.

Schürch CM, Riether C, Ochsenbein AF.

Oncoimmunology. 2013 Jun 1;2(6):e24572. Epub 2013 Apr 16.

Supplemental Content

Loading ...
Support Center